Difficulty: Medium
Average Score: 86%
Practice
The following agents if given to an asthmatic are likely to cause catastrophic bronchospasm:
Correct answer
A
Rationale
In this case, the correct answer is A) Carvedilol. Carvedilol is a non-selective beta-blocker that can cause bronchospasm in asthmatic patients due to its antagonistic effects on beta-2 adrenergic receptors in the lungs, which normally help to dilate the bronchioles. By blocking these receptors, Carvedilol can exacerbate bronchoconstriction in asthmatic individuals, leading to catastrophic bronchospasm.
Option B) Losartan is an angiotensin II receptor antagonist used in hypertension management. It does not directly affect bronchial smooth muscle tone and is not known to cause bronchospasm in asthmatic patients.
Option C) Adenosine is a bronchoconstrictor that is used in diagnostic testing for asthma. While it can induce bronchospasm as part of its intended diagnostic use, it is not typically administered to asthmatic patients as a therapeutic agent.
Option D) Lidocaine (lignocaine) is a local anesthetic that does not have a direct effect on bronchial smooth muscle tone and is not associated with causing catastrophic bronchospasm in asthmatic patients.
Educationally, understanding the effects of different medications on respiratory function is crucial for healthcare professionals, especially when managing patients with conditions like asthma. This knowledge helps in making informed decisions about drug therapy to prevent adverse events and optimize patient outcomes. Asthma management requires a nuanced understanding of medications that can potentially trigger bronchospasm, emphasizing the need for healthcare providers to be well-versed in pharmacology concepts related to respiratory drugs.
Option B) Losartan is an angiotensin II receptor antagonist used in hypertension management. It does not directly affect bronchial smooth muscle tone and is not known to cause bronchospasm in asthmatic patients.
Option C) Adenosine is a bronchoconstrictor that is used in diagnostic testing for asthma. While it can induce bronchospasm as part of its intended diagnostic use, it is not typically administered to asthmatic patients as a therapeutic agent.
Option D) Lidocaine (lignocaine) is a local anesthetic that does not have a direct effect on bronchial smooth muscle tone and is not associated with causing catastrophic bronchospasm in asthmatic patients.
Educationally, understanding the effects of different medications on respiratory function is crucial for healthcare professionals, especially when managing patients with conditions like asthma. This knowledge helps in making informed decisions about drug therapy to prevent adverse events and optimize patient outcomes. Asthma management requires a nuanced understanding of medications that can potentially trigger bronchospasm, emphasizing the need for healthcare providers to be well-versed in pharmacology concepts related to respiratory drugs.